Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
0.1683
-0.0024 (-1.41%)
At close: Oct 30, 2026, 4:00 PM EDT
0.1695
+0.0012 (0.71%)
After-hours: Oct 30, 2026, 7:56 PM EDT
Vistagen Therapeutics Revenue
Vistagen Therapeutics had revenue of $1.48M in the quarter ending June 30, 2026, with 504.92% growth. This brings the company's total for the last twelve months to $2.50M, up 287.31% year-over-year. In the fiscal year ending March 31, 2026, Vistagen Therapeutics had annual revenue of $1.27M with 161.11% growth. That makes Vistagen Therapeutics the 41,906th largest company in the world by revenue and 5,667th in the United States.
Revenue (ttm)
$2.50M
Revenue Growth
+287.31%
P/S Ratio
2.99
Revenue / Employee
$61,000
Employees
41
Market Cap
7.47M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 1.27M | 783.00K | 161.11% |
| Mar 31, 2025 | 486.00K | -578.00K | -54.32% |
| Mar 31, 2024 | 1.06M | 1.29M | - |
| Mar 31, 2023 | -227.00K | -1.34M | - |
| Mar 31, 2022 | 1.11M | 19.40K | 1.78% |
| Mar 31, 2021 | 1.09M | - | - |
| Mar 31, 2020 | - | - | - |
| Mar 31, 2019 | - | - | - |
| Mar 31, 2018 | - | - | - |
| Mar 31, 2017 | 1.25M | - | - |
| Mar 31, 2016 | - | - | - |
| Mar 31, 2015 | - | - | - |
| Mar 31, 2014 | - | - | - |
| Mar 31, 2013 | 200.40K | -1.14M | -85.07% |
| Mar 31, 2012 | 1.34M | -728.80K | -35.19% |
| Mar 31, 2011 | 2.07M | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Exicure | 500.00K |
| CollPlant Biotechnologies | 318.00K |
| Lexaria Bioscience | 194.00K |
| Senti Biosciences Holdings | 55.00K |
| Soligenix | 2.34K |
VTGN News
- 11 days ago - Vistagen selects GATC Health to apply predictive AI to drug development - TheFly
- 11 days ago - Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs - GlobeNewsWire
- 5 weeks ago - SRX Global says adds investment in Onconetix - TheFly
- 5 weeks ago - Vistagen presents data on fasedienol nasal spray at Psych Congress 2026 - TheFly
- 5 weeks ago - Vistagen Reports Positive Findings Supporting Fasedienol's Potential in Very Severe Social Anxiety Disorder - GlobeNewsWire
- 5 weeks ago - Vistagen announces preliminary data from OLE of Palisade-4 Phase 3 study - TheFly
- 5 weeks ago - Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder - GlobeNewsWire
- 7 weeks ago - Vistagen Therapeutics Transcript: AGM 2026 - Transcripts